Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

HER2 and response to paclitaxel in node-positive breast cancer.

Roukos DH.

N Engl J Med. 2008 Jan 10;358(2):197; author reply 198. No abstract available.

PMID:
18193530
2.

HER2 and response to paclitaxel in node-positive breast cancer.

Ferretti G, Felici A, Cognetti F.

N Engl J Med. 2008 Jan 10;358(2):197; author reply 198. doi: 10.1056/NEJMc073152. No abstract available.

3.

HER2 and response to paclitaxel in node-positive breast cancer.

Nash I.

N Engl J Med. 2008 Jan 10;358(2):198; author reply 198-9. No abstract available.

PMID:
18193532
4.

HER2 and response to paclitaxel in node-positive breast cancer.

Mehta R.

N Engl J Med. 2008 Jan 10;358(2):197-8; author reply 198. No abstract available.

PMID:
18193531
5.

HER2 and response to paclitaxel in node-positive breast cancer.

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators.

N Engl J Med. 2007 Oct 11;357(15):1496-506.

6.

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.

Yardley D, Burris H 3rd, Peacock N, Raefsky E, Melnik M, Inhorn R, Shipley D, Hainsworth J.

Breast Cancer Res Treat. 2010 Sep;123(2):471-5. doi: 10.1007/s10549-010-1047-0. Epub 2010 Jul 24.

PMID:
20658263
7.

Genentech's anticancer Mab expected by November.

Robertson D.

Nat Biotechnol. 1998 Jul;16(7):615. No abstract available.

PMID:
9661186
8.

Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.

Ferretti G, Felici A, Papaldo P, Carlini P, Fabi A, Cognetti F.

Oncologist. 2006 May;11(5):533; author reply 534. No abstract available.

9.

Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.

Horiguchi J, Oyama T, Koibuchi Y, Yokoe T, Takata D, Ikeda F, Nagaoka H, Rokutanda N, Nagaoka R, Ishikawa Y, Odawara H, Kikuchi M, Sato A, Iino Y, Takeyoshi I.

Anticancer Res. 2009 Feb;29(2):517-24.

10.

[Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].

Jiang ZF, Shao ZM, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2010 Feb;32(2):158-60. Chinese. No abstract available.

PMID:
20403251
11.

[Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer].

Suzuki M, Kimijima I, Ishii M.

Gan To Kagaku Ryoho. 2009 Sep;36(9):1519-23. Japanese.

PMID:
19755824
12.

[Paclitaxel for treatment of advanced breast cancers].

Ito Y.

Nihon Rinsho. 2000 Apr;58 Suppl:259-64. Review. Japanese. No abstract available.

PMID:
11026004
13.

Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.

Altundag K, Baptista MZ.

Breast J. 2006 Sep-Oct;12(5):497-8. No abstract available.

PMID:
16958977
14.

Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.

[No authors listed]

Oncology (Williston Park). 2005 Jun;19(7):851, 862. No abstract available.

PMID:
16053034
15.

[Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].

Wang LP, Shen KW, Shen ZZ.

Zhonghua Zhong Liu Za Zhi. 2006 Apr;28(4):241-3. Review. Chinese. No abstract available.

PMID:
16875618
16.
17.

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Yaal-Hahoshen N, Safra T.

Isr Med Assoc J. 2006 Jun;8(6):416-21. Review. No abstract available.

18.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N.

N Engl J Med. 2005 Oct 20;353(16):1673-84.

19.

Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.

Horiguchi J, Oyama T, Takata D, Rokutanda N, Nagaoka R, Odawara H, Tokiniwa H, Tozuka K, Kikuchi M, Sato A, Takeyoshi I.

Anticancer Res. 2011 Sep;31(9):3041-6.

PMID:
21868556
20.

[Systemic pharmacotherapy in breast cancer].

Boér K.

Orv Hetil. 2004 Jan 25;145(4):187-92. Review. Hungarian. No abstract available.

PMID:
14978885

Supplemental Content

Support Center